Survodutide* · BI 456906*

Researchers seeking this product for laboratory research can explore PepGen-X.com as a supplier specializing in research-use compounds.

Survodutide is an investigational dual GLP-1 and glucagon receptor agonist being studied for obesity and metabolic dysfunction-associated steatohepatitis (MASH). By combining GLP-1 activity with glucagon signaling, research has demonstrated substantial effects on body weight, appetite, liver fat, and metabolic health.

Research Benefits

Significant weight-loss research with phase 2 studies showing up to approximately 15% mean weight reduction at 46 weeks

Liver-fat reduction with phase 3 data showing substantial reductions in liver fat content

MASH research with clinical evidence of improvement in liver disease activity and fibrosis-related measures

Dual metabolic signaling through GLP-1 and glucagon receptors

Once-weekly formulation investigated in clinical trials

Identified Risks & Side Effects

Nausea and diarrhea are among the most frequently reported adverse effects

Vomiting and other gastrointestinal effects can occur, particularly during dose escalation

Glucose regulation requires study because glucagon and GLP-1 have opposing metabolic effects

Long-term safety remains under investigation as clinical development continues

Not FDA-approved and remains investigational

Route: Subcutaneous in clinical trials | Frequency: Once weekly in clinical trials | FDA Status: Investigational / Not FDA-approved

Researcher Note

Survodutide is an important area of current metabolic and liver-disease research because it combines GLP-1 and glucagon receptor activity. In a phase 2 obesity trial, the 4.8 mg group had a mean 14.9% reduction in body weight at 46 weeks. citeturn0search2

Liver research has been particularly notable. In a 48-week phase 2 MASH trial, 62% of participants receiving 4.8 mg achieved MASH improvement without worsening of fibrosis, compared with 14% receiving placebo. More recent phase 3 data in people with obesity and at-risk MASLD showed a 12.2% mean reduction in body weight and a substantial reduction in liver fat at 48 weeks. citeturn0search0turn0search3

Disclaimer

FDA Status: Not FDA-approved; investigational
Research Classification: Research use only
Compound Type: Dual GLP-1 / glucagon receptor agonist

All products are intended strictly for research and laboratory use only and are not intended for human or veterinary use.